Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
Liebowitz M R, Hollander E, Schneier F, +7 more·Journal of clinical psychopharmacology
The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessive-compulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62% (24/39) of adequately treated patients and 49% (24/49)…